Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
Mbio
|
September 29, 2011
Necrotic enteritis-derived Clostridium perfringens strain with three closely related independently conjugative toxin and antibiotic resistance plasmids
Trudi L Bannam, Xu-Xia Yan, Paul F Harrison, et al.
BMC Genomics
|
May 6, 2016
Perturbation of the two-component signal transduction system, BprRS, results in attenuated virulence and motility defects in Burkholderia pseudomallei
Natalie R Lazar Adler, Elizabeth M Allwood, Deanna Deveson Lucas, et al.
Antimicrobial Agents and Chemotherapy
|
September 22, 2010
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production
Jennifer H Moffatt, Marina Harper, Paul Harrison, et al.
Antimicrobial Agents and Chemotherapy
|
February 13, 2019
Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia
Vanessa E Rees, Deanna S Deveson Lucas, Carla López-Causapé, et al.
Scientific Reports
|
March 1, 2016
Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii
Mohd Hafidz Mahamad Maifiah, Soon-Ee Cheah, Matthew D Johnson, et al.
Antimicrobial Agents and Chemotherapy
|
February 14, 2018
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model
Cornelia B Landersdorfer, Vanessa E Rees, Rajbharan Yadav, et al.
Antimicrobial Agents and Chemotherapy
|
July 10, 2023
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance
Jessica R Tait, Marina Harper, Sara Cortés-Lara, et al.
Antimicrobial Agents and Chemotherapy
|
April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials
Yuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
International Journal of Antimicrobial Agents
|
April 1, 2024
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing
Siobhonne K J Breen, Marina Harper, Carla López-Causapé, et al.
The Lancet. Microbe
|
June 25, 2026
Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations
Siobhonne K J Breen, Sara Cortés-Lara, Jessica R Tait, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
Mbio
|
September 29, 2011
Necrotic enteritis-derived Clostridium perfringens strain with three closely related independently conjugative toxin and antibiotic resistance plasmids
Trudi L Bannam, Xu-Xia Yan, Paul F Harrison, et al.
BMC Genomics
|
May 6, 2016
Perturbation of the two-component signal transduction system, BprRS, results in attenuated virulence and motility defects in Burkholderia pseudomallei
Natalie R Lazar Adler, Elizabeth M Allwood, Deanna Deveson Lucas, et al.
Antimicrobial Agents and Chemotherapy
|
September 22, 2010
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production
Jennifer H Moffatt, Marina Harper, Paul Harrison, et al.
Antimicrobial Agents and Chemotherapy
|
February 13, 2019
Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia
Vanessa E Rees, Deanna S Deveson Lucas, Carla López-Causapé, et al.
Scientific Reports
|
March 1, 2016
Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii
Mohd Hafidz Mahamad Maifiah, Soon-Ee Cheah, Matthew D Johnson, et al.
Antimicrobial Agents and Chemotherapy
|
February 14, 2018
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model
Cornelia B Landersdorfer, Vanessa E Rees, Rajbharan Yadav, et al.
Antimicrobial Agents and Chemotherapy
|
July 10, 2023
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance
Jessica R Tait, Marina Harper, Sara Cortés-Lara, et al.
Antimicrobial Agents and Chemotherapy
|
April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials
Yuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
International Journal of Antimicrobial Agents
|
April 1, 2024
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing
Siobhonne K J Breen, Marina Harper, Carla López-Causapé, et al.
The Lancet. Microbe
|
June 25, 2026
Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations
Siobhonne K J Breen, Sara Cortés-Lara, Jessica R Tait, et al.
Page
of 10